Chemo Combo Kills Resistant Ovarian Cancer Cells
12/08/2011
Two drugs never used together before in treating ovarian cancer killed 70% of cells already resistant to commonly used chemotherapy compounds, concludes a new study published online recently in Gynecologic Oncology...
The Importance Of Echocardiography To Evaluate Cardio Toxicity In Cancer Patients: EUROECHO 2011
12/08/2011
One study presented at the meeting, which is being held in Budapest, Hungary, 7 to 10 December, reports on an initiative using echocardiography to document early warning signs of adverse effects from trastuzumab (Herceptin ®)¹, while the other uses echocardiography to evaluate the protective role of ACE inhibitors and statins on the hearts of cancer patients²...
Breast Cancer Mortality Higher In Hispanic Women
12/08/2011
Hispanic women are more likely to die from breast cancer than non-Hispanic white women, according to research presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011. "This difference may be associated with a tumor phenotype that is less responsive to chemotherapy," said Kathy B. Baumgartner, Ph.D...
Dual HER2 Blockade Significantly Extends Progression-Free Survival
12/08/2011
Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients with metastatic HER2-positive breast cancer compared with patients who received the combination therapy with placebo...
Everolimus in combination with exemestane has shown promise for the treatment of breast cancer. "For postmenopausal patients with hormone receptor (HR)-positive metastatic breast cancer, the addition of everolimus to exemestane markedly improves the duration of disease control," said Gabriel N. Hortobagyi, M.D...
Data evaluated by an independent review committee revealed that the addition of bevacizumab to trastuzumab and docetaxel significantly improved progression-free survival in HER2-positive breast cancer, despite findings from an investigator assessment that the improvement was present but statistically non-significant. Luca Gianni, M.D...
In an international Phase III randomized study, everolimus, when combined with the hormonal therapy exemestane, has been shown to dramatically improve progression-free survival, according to research from The University of Texas MD Anderson Cancer Center...
New Protocols Improve Detection Of MicroRNAs For Diagnosis
12/08/2011
MicroRNAs (miRNAs) that regulate processes including fertilization, development, and aging show promise as biomarkers of disease. They can be collected from routinely collected fluids such as blood, saliva, and urine. However, a number of factors can interfere with the accuracy of miRNA tests...
TAU Develops Tumor Destruction Method That Also Creates Immunity
12/08/2011
Even when surgical tumor removal is combined with a heavy dose of chemotherapy or radiation, there's no guarantee that the cancer will not return. Now researchers at Tel Aviv University are strengthening the odds in favor of permanent tumor destruction - and an immunity to the cancer's return - with a new method of tumor removal...
Many Women Not Receiving Recommended Breast Cancer Adjuvant Treatment
12/08/2011
A first-of-its kind study led by Xiao-Cheng Wu, MD, MPH, Associate Professor of Public Health at LSU Health Sciences Center New Orleans, reports that a significant number of women are not receiving guideline-recommended treatment for breast cancer and what factors contribute. The research is published online in the Journal of Clinical Oncology...